Literature DB >> 21416464

Vstm3 is a member of the CD28 family and an important modulator of T-cell function.

Steven D Levin1, David W Taft, Cameron S Brandt, Christoph Bucher, Edward D Howard, Eric M Chadwick, Janet Johnston, Angela Hammond, Kristen Bontadelli, Daniel Ardourel, LuAnn Hebb, Anitra Wolf, Thomas R Bukowski, Mark W Rixon, Joseph L Kuijper, Craig D Ostrander, James W West, Janine Bilsborough, Brian Fox, Zeren Gao, Wenfeng Xu, Fred Ramsdell, Bruce R Blazar, Katherine E Lewis.   

Abstract

Members of the CD28 family play important roles in regulating T-cell functions and share a common gene structure profile. We have identified VSTM3 as a protein whose gene structure matches that of the other CD28 family members. This protein (also known as TIGIT and WUCAM) has been previously shown to affect immune responses and is expressed on NK cells, activated and memory T cells, and Tregs. The nectin-family proteins CD155 and CD112 serve as counter-structures for VSTM3, and CD155 and CD112 also bind to the activating receptor CD226 on T cells and NK cells. Hence, this group of interacting proteins forms a network of molecules similar to the well-characterized CD28-CTLA-4-CD80-CD86 network. In the same way that soluble CTLA-4 can be used to block T-cell responses, we show that soluble Vstm3 attenuates T-cell responses in vitro and in vivo. Moreover, animals deficient in Vstm3 are more sensitive to autoimmune challenges indicating that this new member of the CD28 family is an important regulator of T-cell responses.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21416464      PMCID: PMC3733993          DOI: 10.1002/eji.201041136

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  47 in total

Review 1.  The B7-CD28 superfamily.

Authors:  Arlene H Sharpe; Gordon J Freeman
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

2.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

3.  Non-synonymous variant (Gly307Ser) in CD226 is associated with susceptibility to multiple autoimmune diseases.

Authors:  Amit K Maiti; Xana Kim-Howard; Parvathi Viswanathan; Laura Guillén; Xiaoxia Qian; Adriana Rojas-Villarraga; Celi Sun; Carlos Cañas; Gabriel J Tobón; Koichi Matsuda; Nan Shen; Alejandra C Cherñavsky; Juan-Manuel Anaya; Swapan K Nath
Journal:  Rheumatology (Oxford)       Date:  2010-03-24       Impact factor: 7.580

4.  The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.

Authors:  Noa Stanietsky; Hrvoje Simic; Jurica Arapovic; Amir Toporik; Ofer Levy; Amit Novik; Zurit Levine; Meirav Beiman; Liat Dassa; Hagit Achdout; Noam Stern-Ginossar; Pinhas Tsukerman; Stipan Jonjic; Ofer Mandelboim
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-07       Impact factor: 11.205

5.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

6.  Overexpression of the CD155 gene in human colorectal carcinoma.

Authors:  D Masson; A Jarry; B Baury; P Blanchardie; C Laboisse; P Lustenberger; M G Denis
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

7.  Recombinant soluble human FcgammaR1A (CD64A) reduces inflammation in murine collagen-induced arthritis.

Authors:  Jeff L Ellsworth; Nels Hamacher; Brandon Harder; Ken Bannink; Thomas R Bukowski; Kelly Byrnes-Blake; Sara Underwood; Colleen Oliver; Kimberly S Waggie; Claire Noriega; LuAnne Hebb; Mark W Rixon; Katherine E Lewis
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 8.  Autoimmunity risk alleles in costimulation pathways.

Authors:  Lisa M Maier; David A Hafler
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination.

Authors:  Lars Svensson; Khairul-Bariah Abdul-Majid; Jan Bauer; Hans Lassmann; Robert A Harris; Rikard Holmdahl
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

10.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1.

Authors:  Norihiko Watanabe; Maya Gavrieli; John R Sedy; Jianfei Yang; Francesca Fallarino; Susan K Loftin; Michelle A Hurchla; Natalie Zimmerman; Julia Sim; Xingxing Zang; Theresa L Murphy; John H Russell; James P Allison; Kenneth M Murphy
Journal:  Nat Immunol       Date:  2003-06-08       Impact factor: 25.606

View more
  113 in total

1.  Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering.

Authors:  Katharina F Stengel; Kristin Harden-Bowles; Xin Yu; Lionel Rouge; Jianping Yin; Laëtitia Comps-Agrar; Christian Wiesmann; J Fernando Bazan; Dan L Eaton; Jane L Grogan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

Review 2.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses.

Authors:  Robert J Johnston; Xin Yu; Jane L Grogan
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

4.  TIGIT-positive circulating follicular helper T cells and sickle cell alloimmunization.

Authors:  France Pirenne
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 5.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

6.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

7.  T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Authors:  Man Li; Pengyan Xia; Ying Du; Shengwu Liu; Guanling Huang; Jun Chen; Honglian Zhang; Ning Hou; Xuan Cheng; Luyu Zhou; Peifeng Li; Xiao Yang; Zusen Fan
Journal:  J Biol Chem       Date:  2014-05-09       Impact factor: 5.157

8.  Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Authors:  Heidi Harjunpää; Stephen J Blake; Elizabeth Ahern; Stacey Allen; Jing Liu; Juming Yan; Viviana Lutzky; Kazuyoshi Takeda; Amy Roman Aguilera; Camille Guillerey; Deepak Mittal; Xian Yang Li; William C Dougall; Mark J Smyth; Michele W L Teng
Journal:  Oncoimmunology       Date:  2018-03-26       Impact factor: 8.110

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.